Board of Directors
Paul Anderson, Managing Director
Paul has over 20 years’ experience in the medical device and cellular therapeutic fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. This encompasses applying the regulatory framework to the product, rebating pathways, marketing, sales, developing key option leader relationships, strategic and financial planning. Paul has a strong track record with his previous board position with Verigen Australia Pty Ltd, a human cell therapies company.
Dr Stewart James Washer, Chairman
Stewart has 20 years of CEO and Board experience in medical technology, biotech and agrifood companies. He is currently the Chairman of Cynata Therapeutics Ltd (ASX:CYP) who are developing stem cell therapies, Chairman of Minomic International Ltd who have an accurate non-invasive test for prostate cancer and Investment Director with Bioscience Managers.
Previously Stewart was the CEO of Calzada Ltd (ASX:CZD), the founding CEO of Phylogica Ltd (ASX:PYC) and the CEO of Celentis where he managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 scientists and $130m revenues. Stewart was Chairman of iSonea Ltd (ASX:ISN), Resonance Health Ltd (ASX:RHT) and Hatchtech Pty Ltd, a Director of iCeutica Pty Ltd, Immuron Ltd (ASX:IMC) and AusBiotech Ltd. He was also a Senator with Murdoch University.
Matt Callahan, Corporate Adviser
Mr Callahan is an experienced life sciences executive based in Philadelphia. He is the founding CEO of iCeutica Inc and a co-inventor of some of the technologies that comprise the SoluMatrix Fine Particle Technology™ platform that iCeutica uses to develop new pharmaceuticals. iCeutica has developed two products to date that have received FDA approval, has 1 pending approval and 2 products in late stage development. He has more than 18 years legal, IP and investment management experience and is also a director of Glycan Bioscience LLC and founding CEO of Churchill Pharma.
Mr Callahan has worked as an investment director for two venture capital firms investing in life sciences, clean technology and other sectors and was General Manager and General Counsel with Australian listed technology and licensing company ipernica (now Nearmap ASX:NEA), where he was responsible for the licensing programs that generated more than $120M in revenue.
Professor Lars Lidgren, Board Member
M.D., Ph.D. Professor in Orthopedics at the University Hospital of Lund. Professor Lidgren leads a productive regenerative medicine research group at the University Hospital of Lund. The hospital is a member of the ISOC group of worldwide leading hospitals and Professor Lidgren is an honorary member and past president of several major societies. He initiated the worldwide Bone and Joint Decade 2000-2010 and is a successful serial entrepreneur who founded the companies Scandimed (Biomet), Bone Support, AMeC and GWS in Sweden.
Mr Qi Xiao Zhou, Board Member
Mr Zhou has 15 years’ experience within China as a senior business manager and executive. He has been General Manager of Shenzhen Lightning Digital Technology Co Ltd since 2001, focused on the manufacture and distribution of Semiconductor/Integrated Circuit technology.
Mr Zhou has experience within the public markets in Hong Kong, China and Taiwan and brings to the Board a wealth of business management and business development experience within the Asian regions. In particular Mr Zhou has broad connections and experience in the licensing of technologies into China and licensing into the Asian region.